• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

化学合成二价A群链球菌疫苗的免疫原性和安全性

Immunogenicity and Safety of a Chemically Synthesized Divalent Group A Streptococcal Vaccine.

作者信息

Wu Yongxiang, Li Suhua, Luo Yanting, Zhao Yunyue, Wang Jiarui, Dong Ruimin, Xie Xujing, Zhu Jieming, Liu Jinlai

机构信息

Department of Cardiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China.

出版信息

Can J Infect Dis Med Microbiol. 2018 Feb 28;2018:4702152. doi: 10.1155/2018/4702152. eCollection 2018.

DOI:10.1155/2018/4702152
PMID:29682128
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5851172/
Abstract

BACKGROUND

Group A streptococcus (GAS) infections and poststreptococcal sequelae remain a health problem worldwide, which necessitates searching for an effective vaccine, while no licensed GAS vaccine is available. We have developed a divalent peptide vaccine composed of 84 amino acids to cover the main GAS serotypes (M1 and M12 streptococci) in China, and herein, we aimed to evaluate immunogenicity and safety of this vaccine.

METHODS

Mice were immunized with the vaccine. ELISA, indirect bactericidal test, and immunofluorescent assay were used to study immunogenicity. GAS challenge assay was used to test the protective effect. Safety was tested by histopathological analysis.

RESULTS

Immunized group mice (=16) developed higher titer antibody after immunization than nonimmunized group mice (=16) did. This antibody can deposit on the surface of GAS and promote killing of GAS, resulting in 93.1% decrease of M1 GAS and 89.5% of M12 GAS. When challenged with M1 and M12 streptococci, immunized group mice had a higher survival rate (87.5% and 75%) than nonimmunized group mice (37.5% and 25%). No autoimmune reactions were detected on organs of mice.

CONCLUSION

The results suggest that this vaccine shows fair immunogenicity and safety, which will lead our research on GAS vaccine into clinical trial.

摘要

背景

A 组链球菌（GAS）感染及链球菌感染后后遗症仍是全球范围内的健康问题，这使得研发有效的疫苗成为必要，然而目前尚无获得许可的 GAS 疫苗。我们研发了一种由 84 个氨基酸组成的二价肽疫苗，以覆盖中国主要的 GAS 血清型（M1 和 M12 链球菌），在此，我们旨在评估该疫苗的免疫原性和安全性。

方法

用该疫苗免疫小鼠。采用酶联免疫吸附测定（ELISA）、间接杀菌试验和免疫荧光测定来研究免疫原性。采用 GAS 攻击试验来测试保护效果。通过组织病理学分析来检测安全性。

结果

免疫组小鼠（n = 16）免疫后产生的抗体滴度高于未免疫组小鼠（n = 16）。该抗体可沉积在 GAS 表面并促进 GAS 的杀灭，导致 M1 GAS 减少 93.1%，M12 GAS 减少 89.5%。当用 M1 和 M12 链球菌攻击时，免疫组小鼠的存活率（87.5%和 75%）高于未免疫组小鼠（37.5%和 25%）。在小鼠器官上未检测到自身免疫反应。

结论

结果表明该疫苗具有良好的免疫原性和安全性，这将推动我们对 GAS 疫苗的研究进入临床试验阶段。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d79/5851172/6d71144b9a1b/CJIDMM2018-4702152.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d79/5851172/cc109f2408bf/CJIDMM2018-4702152.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d79/5851172/1ded92d2d691/CJIDMM2018-4702152.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d79/5851172/9dd2df62969c/CJIDMM2018-4702152.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d79/5851172/49fee011520b/CJIDMM2018-4702152.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d79/5851172/6d71144b9a1b/CJIDMM2018-4702152.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d79/5851172/cc109f2408bf/CJIDMM2018-4702152.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d79/5851172/1ded92d2d691/CJIDMM2018-4702152.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d79/5851172/9dd2df62969c/CJIDMM2018-4702152.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d79/5851172/49fee011520b/CJIDMM2018-4702152.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d79/5851172/6d71144b9a1b/CJIDMM2018-4702152.005.jpg

相似文献

1
Immunogenicity and Safety of a Chemically Synthesized Divalent Group A Streptococcal Vaccine.化学合成二价A群链球菌疫苗的免疫原性和安全性
Can J Infect Dis Med Microbiol. 2018 Feb 28;2018:4702152. doi: 10.1155/2018/4702152. eCollection 2018.
2
Immunogenicity of a divalent group A streptococcal vaccine.A 型链球菌二价疫苗的免疫原性。
Rheumatol Int. 2013 Apr;33(4):1013-20. doi: 10.1007/s00296-012-2455-8. Epub 2012 Aug 8.
3
Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.A群链球菌候选疫苗和全长M蛋白在皮肤和侵袭性疾病模型中的不同疗效
mBio. 2016 Jun 14;7(3):e00618-16. doi: 10.1128/mBio.00618-16.
4
Role of streptococcal IgG Fc receptor in tissue deposition of IgG in rabbits immunized with Streptococcus pyogenes.化脓性链球菌免疫家兔中链球菌IgG Fc受体在IgG组织沉积中的作用
APMIS. 1992 Jun;100(6):567-74. doi: 10.1111/j.1699-0463.1992.tb00912.x.
5
A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.一种新型的经鼻内接种的A群9型链球菌活载体疫苗可保护小鼠免受9型A群链球菌的攻击感染。
Clin Vaccine Immunol. 2014 Sep;21(9):1343-9. doi: 10.1128/CVI.00330-14. Epub 2014 Jul 23.
6
Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.由包含10株表达源自A组链球菌的高度流行M蛋白抗原的乳酸乳球菌菌株的鼻内多价疫苗诱导的保护性免疫。
Microbiol Immunol. 2018 Jun;62(6):395-404. doi: 10.1111/1348-0421.12595. Epub 2018 Jun 11.
7
Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.重组多价A群链球菌疫苗在健康成年人中的安全性和免疫原性：1期试验
JAMA. 2004 Aug 11;292(6):709-15. doi: 10.1001/jama.292.6.709.
8
A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes.多组分疫苗可提供针对 A 群链球菌血清型的局部和全身感染的免疫。
mBio. 2019 Nov 26;10(6):e02600-19. doi: 10.1128/mBio.02600-19.
9
Evaluation of synthetic, M type-specific peptides as antigens in a multivalent group A streptococcal vaccine.评估合成的M型特异性肽作为多价A群链球菌疫苗中的抗原。
Vaccine. 2003 Jun 20;21(21-22):2698-703. doi: 10.1016/s0264-410x(03)00165-8.
10
Cross-serotype protection against group A Streptococcal infections induced by immunization with SPy_2191.免疫 SPy_2191 可诱导针对 A 群链球菌感染的交叉型保护。
Nat Commun. 2020 Jul 15;11(1):3545. doi: 10.1038/s41467-020-17299-x.

本文引用的文献

1
Re-emergence of scarlet fever: old players return?猩红热的再度出现：老问题重现？
Expert Rev Anti Infect Ther. 2016 Aug;14(8):687-9. doi: 10.1080/14787210.2016.1195684. Epub 2016 Jun 13.
2
Streptococcus pyogenes and re-emergence of scarlet fever as a public health problem.化脓性链球菌与猩红热作为公共卫生问题的再度出现。
Emerg Microbes Infect. 2012 Jul;1(7):e2. doi: 10.1038/emi.2012.9. Epub 2012 Jul 11.
3
StreptInCor: a model of anti-Streptococcus pyogenes vaccine reviewed.抗化脓性链球菌疫苗模型StreptInCor综述。
Auto Immun Highlights. 2013 Oct 4;4(3):81-5. doi: 10.1007/s13317-013-0053-8. eCollection 2013 Dec.
4
Group a streptococcal diseases and their global burden.A 组链球菌疾病及其全球负担。
Curr Top Microbiol Immunol. 2013;368:1-27. doi: 10.1007/82_2012_280.
5
Scarlet fever epidemic, Hong Kong, 2011.2011 年香港猩红热疫情。
Emerg Infect Dis. 2012 Oct;18(10):1658-61. doi: 10.3201/eid1810.111900.
6
Immunogenicity of a divalent group A streptococcal vaccine.A 型链球菌二价疫苗的免疫原性。
Rheumatol Int. 2013 Apr;33(4):1013-20. doi: 10.1007/s00296-012-2455-8. Epub 2012 Aug 8.
7
Outbreak of scarlet fever associated with emm12 type group A Streptococcus in 2011 in Shanghai, China.2011 年中国上海爆发与emm12 型 A 组链球菌相关的猩红热疫情。
Pediatr Infect Dis J. 2012 Sep;31(9):e158-62. doi: 10.1097/INF.0b013e31825874f3.
8
New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci.新型 30 价 M 蛋白疫苗引发针对 A 组链球菌非疫苗血清型的交叉调理抗体。
Vaccine. 2011 Oct 26;29(46):8175-8. doi: 10.1016/j.vaccine.2011.09.005. Epub 2011 Sep 13.
9
The streptococcal M protein: a highly versatile molecule.链球菌 M 蛋白：一种高度多功能的分子。
Trends Microbiol. 2010 Jun;18(6):275-82. doi: 10.1016/j.tim.2010.02.007. Epub 2010 Mar 27.
10
Global emm type distribution of group A streptococci: systematic review and implications for vaccine development.A群链球菌的全球emm型分布：系统评价及对疫苗研发的启示
Lancet Infect Dis. 2009 Oct;9(10):611-6. doi: 10.1016/S1473-3099(09)70178-1.